[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AponiaAnalytics Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1816152863069925376.png) aponia_analytics [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) on x 4964 followers
Created: 2025-07-20 19:31:36 UTC

🦉 In SUSTAIN-10, semaglutide reduced HbA1c and weight more than liraglutide, but had higher GI side effects. Tirzepatide—dual GLP-1/GIP agonist—showed superior glycemic control in meta-analysis.

#Semaglutide #Tirzepatide $NVO $LLY $AZN $SNY $GSK $PFE


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947016561270608092/c:line.svg)

**Related Topics**
[pfe](/topic/pfe)
[manat](/topic/manat)
[$gsk](/topic/$gsk)
[$sny](/topic/$sny)
[$lly](/topic/$lly)
[superior](/topic/superior)
[$nvo](/topic/$nvo)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/AponiaAnalytics/status/1947016561270608092)